Patients with presumably benign thyroid disease (multinodular goitre, solitary thyroid nodule, toxic goitre, etc.) Patients with thyroid carcinoma (biopsy-proved) Total thyroidectomy preference by the primary surgeon

Thyroid Carcinoma

Thyroid Papillary Carcinoma

Multinodular Goiter, Adolescent

Solitary Thyroid Nodule

Thyroid Diseases

Multifocal Dysplasia

Aspiration

Thyroid Nodule

Thyroid Cancer, Papillary

Thyroid Neoplasms

Thyroid Goiter

Final total thyroidectomy histopathology report should be available for correlations with preoperatively determined malignancy predictive factors, Bethesda (cytology) and TI-RADS (ultrasound findings)

Total thyroidectomy (TT)

Umraniye Education and Research Hospital, Health Sciences Universit

Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases

Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial

Malignancy risk factors: 1. Demographics (Age and gender-Male/Female), 2. Smoking history (Yes/No, duration and number/day), 3. Iodine-deficient diet (Yes/No), 4. Born at an endemic area (Yes/No), 5. Presence in an endemic area (Yes/No), 6. Radiation exposure (Yes/No), 7. Radiation treatment during childhood (Yes/No), 8. Head and neck carcinoma (Yes/No), 9. Other carcinoma history (Yes/No, if yes specify.........) 10. Family history of thyroid disease (Yes/No), 11. Family history of other carcinomas (Yes/No), 12. Personal history of thyroid carcinoma/surgery (Yes/No, if yes, pathology……..), 13. Personal history of other carcinomas (e.g. colonic polyps? breast disease?......) 14. Genetic disorders (Yes/No), 15. Obesity (Body mass index - ? kg/m2), 16. Diabetes mellitus (Yes/No) should be evaluated for each patient before surgery- The number of risk factors will be compared with malignancy rate found at final histopathology report.

Bethesda score-FNA cytology report- as I, II, III, IV, V or VI. Cytology report will be compared with final histology report for each patient for malşgnancy rate and multifocality I. Nondiagnostic or unsatisfactory, II. Benign, III. Atypia of undetermined significance (AUS) or follicular lesion of undetermined significance (FLUS), IV. Follicular neoplasm or suspicious for a follicular neoplasm-Preoperative cytology category will be compared with postoperative final histopathology report for malignancy rate, multifocality and cases with cytology-histopathology discrepancy will be evaluated further for biopsy techniques and cytology mis-interpretations.
V. Suspicious for malignancy, VI. Malignant.

TI-RADS score-Ultrasound evaluation of thyroid nodues- as I, II, III, IV or V. TI-RADS scores will be compared with final histopathology report to see malignancy rates and accuracy of TI-RADS.
TI-RADS 1: Normal thyroid gland. No focal lesion. TI-RADS 2: Benign nodules. Noticeably benign pattern (0% risk of malignancy) TI-RADS 3: Probably benign nodules (<5% risk of malignancy)
TI-RADS 4:
4a - Undetermined nodules (5-10% risk of malignancy) Score of 1.
4b - Suspicious nodules (10-50% risk of malignancy) Score of 2.
4c - Highly suspicious nodules (50-85% risk of malignancy) Score of 3-4 TI-RADS 5: Probably malignant nodules (>85% risk of malignancy) Score of 5 or higher TI-RADS 6: Biopsy-proven malignancy

Final histopathology report-After surgery (all patients should have a final histopathology report after total thyroidectomy operation). Final histology report will be correlated to Malignancy risk factors (number), Bethesda category (accuracy, false negativity/positivity) and TI-RADS (accuracy, false negativity/positivity)

All Excel documents will be available (Patient initials and medical record numbers shaded XX). Demographics, BMI, malignancy risk factors, Bethesda and TI-RADS scores and final histopathology reports

Ethem Unal, M.D., PhD, Associate Prof of Surgery & Surgic

Assoc. Professor of General Surgery and Surgical Oncology

Umraniye Education and Research Hospital

LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

Bipolar Disorder

Obesity

3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)

LIRAGLUTIDE

Placebo

Lindner Center of HOPE

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

A Randomized, Placebo-Controlled Study of Liraglutide 3mg Daily (Saxenda®) in Obese or Overweight Patients With Stable Bipolar Disorder

The primary objective of this study is to evaluate the efficacy of liraglutide 3.0 mg sc injection(in combination with a reduced calorie diet and increased physical activity) compared with placebo for reducing body weight in obese or overweight adults with stable BP, as measured by percent change in body weight.

Susan McElroy

Chief Research Officer

We will conduct a single-center, randomized, placebo-controlled, double-blind, parallel-group, 2-arm clinical trial of liraglutide 3.0 mg sc injection in 60 obese or overweight outpatients with stable BP.

The Nos surgical (NS) group includes 15 patients for whom bariatric surgery is planned. Body mass index (BMI) of this group of patients is ≥40 Kg/m2.

The Surgical (S) group includes 15 patients who had undergone Roux-en-Y bariatric surgery 2 to 3 months before inclusion in the study

Morbid Obesity

600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration

thyroid neoplasms/fetma

Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases

Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

Levothyroxine (L-T4) Absorption After Bariatric Surgery

Den mest kompletta databasen med medicinska örter som stöds av vetenskapen